Mystical Experience Score: The MEQ-30 Outcome Predictor

There is one number that keeps showing up in the modern psychedelic literature when researchers try to predict who gets better and who does not. It is not dose. It is not setting score. It is not pre-session symptom severity. It is the score on a 30-item questionnaire administered the day of dosing. Across 900-plus integration sessions, the participants who hold up best at the six-month and twelve-month mark are not always the ones with the most intense visuals. They are the ones whose sessions cross a specific phenomenological threshold that the MEQ-30 was built to measure.

The MEQ-30, validated by Barrett, Johnson, and Griffiths in 2015 in the Journal of Psychopharmacology, is the standard outcome measure used at Johns Hopkins, NYU, COMPASS Pathways, Usona, and most other modern psilocybin trial sites. It scores four factors. It produces a percentage. And the threshold it identifies, conventionally 60 percent on all four factors, has held up as a predictor of long-term clinical change across multiple indications. The instrument now exists in six-plus languages by 2024 and is the single most widely cited acute outcome variable in the field.

The frame for this article is research literacy rather than self-administration. The MEQ-30 is not a diagnostic instrument and the score is not a goal. Understanding what it measures, why it predicts outcomes, and where it falls short is the substance of being an informed participant or operator. For deeper coverage of the related neuroscience and integration practice, see the default mode network and what happens in an integration session.

What Is the MEQ-30 and Where Did It Come From?

The MEQ-30 is a 30-item self-report questionnaire designed to measure the subjective intensity of mystical-type experiences induced by psychedelic substances. Barrett, Johnson, and Griffiths revalidated the instrument in 2015 using confirmatory factor analysis on data from 1,602 participants who had taken psilocybin (Barrett et al., 2015). It is now the standard acute outcome measure across modern psilocybin research.

The instrument traces back to Walter Pahnke's 1963 Good Friday experiment and the descriptive framework of mystical experience drawn from William James and W. T. Stace. The Griffiths 2006 baseline psilocybin study used a longer 100-item precursor. Barrett's 2015 work distilled that older instrument down to thirty items, validated the four-factor structure, and produced what is now the working clinical-research version. The 30-item count is not arbitrary. It is the smallest set that preserves factor-level reliability without losing dimensional resolution.

Each item is rated on a 0-to-5 Likert scale, where 0 means "none, not at all" and 5 means "extreme, more than any other time in my life." Scores are summed within each of the four factor subscales and then expressed as a percentage of the maximum possible score on that subscale. A complete mystical experience is conventionally defined as scoring at or above 60 percent on all four factors simultaneously. That threshold, not the total score, is what the predictive literature most often anchors on.

The Four Factors the MEQ-30 Measures

The MEQ-30 measures four distinct dimensions of psychedelic phenomenology, each scored independently and required at the 60 percent threshold for a complete mystical experience designation. The four-factor structure has held up across multiple validation samples and is now the operational definition used across the field. Each factor captures a different facet of what participants describe after high-dose sessions.

Mystical Experience: Unity and Noetic Quality

This is the largest factor, comprising 15 of the 30 items. It covers internal and external unity, the sense of sacredness, the noetic quality which means the conviction that what was experienced was more real than ordinary reality, and what Stace called the "objectivity" of the encounter. MacLean and colleagues in 2012, publishing in the Journal of Psychopharmacology, demonstrated that the mystical-experience subscale specifically predicted enduring increases in the personality domain of Openness, providing additional evidence that this factor carries the strongest long-term signal. This factor carries the most predictive weight in outcome studies.

Positive Mood

This factor includes six items measuring joy, peace, awe, and the feeling of being blessed. It is not redundant with the mystical experience factor because positive affect can occur without unity phenomena and unity phenomena can occur without positive affect. The factor structure separates them deliberately. The Griffiths 2006 baseline data showed that positive mood often persists into the integration window even when the mystical content does not.

Transcendence of Time and Space

This factor measures the felt sense that ordinary temporal and spatial experience has fallen away. Six items capture the dissolution of clock time, the sense of being outside of space, and the experience of timelessness or eternity. The phenomenology is what participants most often struggle to describe afterward, which is part of why it gets its own factor rather than being collapsed into the broader mystical experience subscale.

Ineffability and Paradoxicality

The final factor, comprising three items, captures the structural difficulty of describing the experience in language at all. Ineffability is the felt sense that words are inadequate. Paradoxicality is the sense that the experience contained mutually contradictory truths that nonetheless felt simultaneously valid. This factor is small in item count but disproportionately important phenomenologically. Participants whose sessions score highly here are the ones who, two weeks later, still struggle to tell anyone what happened.

Why Does the MEQ-30 Predict Long-Term Outcomes?

Across alcohol use disorder, depression, anxiety, smoking cessation, and cancer-distress trials, higher MEQ-30 scores at the dosing session correlate with larger reductions in symptom load at six and twelve months. Ko and colleagues in 2023 demonstrated this in a psilocybin cancer-distress sample, finding that participants meeting the complete mystical experience threshold showed significantly larger improvements in depression and anxiety than those who did not. The pattern repeats across indications.

The mechanism is debated. One reading is that MEQ-30 is a proxy for dose-adequate receptor occupancy, and the predictive signal is really a dose-response curve in disguise. A second reading is that the mystical experience itself causes a perspective shift that drives behavior change, an interpretation Griffiths and colleagues in 2006, publishing in Psychopharmacology, defended in the baseline study that established psilocybin's capacity to occasion personally and spiritually significant experience. A third reading is that participants with the constitutional capacity to surrender into the experience are also the participants with the integration capacity to make use of it afterward. The current data cannot fully separate these.

The Alcohol Use Disorder Signal

Bogenschutz and colleagues, in the 2022 JAMA Psychiatry trial of psilocybin for alcohol use disorder, found that MEQ-30 scores at the first dosing session predicted heavy drinking day reductions at thirty-two weeks. The participants whose sessions cleared the complete mystical experience threshold sustained roughly twice the percentage reduction in heavy drinking days at follow-up compared to those whose sessions did not. The signal was robust enough to survive correction for baseline severity.

The Depression Signal

Across the COMPASS Pathways COMP360 program and the Usona Phase 2 psilocybin-for-depression data, MEQ-30 scores correlated with MADRS and QIDS reduction at three and six months. The Davis 2021 JAMA Psychiatry psilocybin-for-major-depression trial reported similar findings at the dose-session level. Earlier, Ross and colleagues in 2016, publishing in the Journal of Psychopharmacology, reported that single-dose psilocybin produced rapid and sustained antidepressant and anxiolytic effects in a cancer-distress sample, with mystical-experience intensity mediating the long-term clinical change. The pattern is consistent enough that MEQ-30 is now standard in essentially every modern depression-indication trial design.

The Smoking Cessation Signal

Garcia-Romeu's original 2014 pilot data, published with Griffiths and Johnson, showed that biologically verified smoking abstinence at twelve months correlated with peak MEQ scores during the dosing sessions. Participants whose sessions met the mystical-experience threshold were substantially more likely to remain abstinent at follow-up than those whose did not, in a sample where the overall abstinence rate at six months was approximately 80 percent.

What Are MEQ4 and CEQ7, and Why Do They Exist?

Garcia-Romeu, Strickland, and Johnson in 2024, publishing in Psychedelic Medicine (DOI 10.1089/psymed.2023.0046), introduced two ultra-short instruments derived from the MEQ-30 and the Challenging Experience Questionnaire respectively. The MEQ4 is a four-item version of the MEQ-30. The CEQ7 is a seven-item version of the CEQ. Both exist because the full instruments, while psychometrically strong, can fatigue participants in trial protocols that involve extensive measurement at multiple time points.

The MEQ4 retains the predictive validity of the longer instrument while reducing administration burden to under a minute. The four items were selected by item-response-theory analysis to preserve discrimination at the complete-mystical-experience threshold while dropping items that contributed less to the factor structure. The result is a screen-and-flag instrument suitable for trial designs that need a session-level snapshot rather than a full phenomenological inventory.

Why a Challenging Experience Short Form Matters

The CEQ7 is the parallel short form for the Challenging Experience Questionnaire, which measures the difficult or distressing dimensions of the same session. The reason it exists alongside the MEQ4 is methodological. Outcome models that only measure mystical-experience intensity, without measuring the challenging-experience load, systematically underestimate the difficulty of the participant's journey. A high MEQ4 score in the presence of a high CEQ7 score is a different clinical signal than a high MEQ4 score alone. The 2024 short forms enable both to be captured cheaply.

The Practical Use Case

For operators and clinicians, the practical implication is that even a brief end-of-session check-in can capture predictive information about the session's likely integration trajectory. The MEQ4 takes under a minute. The CEQ7 takes about ninety seconds. Together they produce a session-level snapshot that informs the integration plan in a way that an unstructured "how was it" conversation does not. This is one of the few places where structured measurement adds clinical value rather than just data-collection burden.

Where the MEQ-30 Falls Short

The MEQ-30 is a strong predictor in research samples but it is not a clinical instrument and it carries three structural limitations that matter for honest interpretation. Conflating the instrument with a diagnostic measure is a common error. Treating the 60 percent threshold as a target rather than a descriptor is another. The third limitation is conceptual, and it is the one critics of the mystical-experience framework press on hardest.

It Is a Correlate, Not a Mechanism

The MEQ-30 score correlates with outcome but does not establish that the mystical experience causes the outcome. The alternative explanations, including dose-adequate receptor occupancy and constitutional surrender capacity, are not ruled out by the correlation. Recent dismantling studies, including arguments from Olson and others that non-hallucinogenic 5-HT2A agonists may produce some of the same plasticity effects, have pressed on this question. The current consensus is that MEQ-30 captures something real and predictive, without claiming to fully explain the mechanism.

It Cannot Be Aimed At

Participants who go into a session aiming for a complete mystical experience score reliably produce lower scores than participants who go in with looser intentions. The phenomenology is associated with surrender, and surrender does not survive goal-locking. This is one of the practical paradoxes of the instrument. The thing that predicts the outcome cannot be pursued directly. It can only be allowed.

It Does Not Capture Challenging Experiences

By design, the MEQ-30 measures the mystical and positive dimensions. It does not capture the difficult, frightening, or destabilizing dimensions of the same session. The CEQ and CEQ7 are the parallel instruments for that domain. A session that scored high on MEQ-30 but also high on the CEQ is a different integration challenge than a session that scored high on MEQ-30 alone. Outcome models that ignore the CEQ side systematically misread the participant's actual journey.

Cultural and Religious Framing Concerns

Some critics have argued that the mystical-experience framework imports a specifically Western, William-James-derived conception of religious experience and applies it cross-culturally in a way that may not generalize. The six-plus language translations and cross-cultural validation work address this partially. The deeper critique, that the very category of "mystical experience" is culturally loaded, remains a live question in the field. The instrument is widely used. It is not above critique.

"The participants who score highest on the MEQ-30 are almost never the ones who went into the session trying to. They are the ones who went in with curiosity, an intention they could let go of, and a willingness to be surprised by what surfaced. Aiming at the score suppresses the score. That paradox is the whole instrument."

What Should Founders Take Away From the MEQ-30 Literature?

The practical takeaway is not to optimize for the score. It is to understand that experiential intensity is a predictor of clinical outcome, and to prepare in ways that support intensity rather than suppress it. Across 900-plus integration sessions, the participants whose sessions cleared the complete-mystical-experience threshold tended to share a small number of preparation patterns rather than a single technique. The patterns are not glamorous. They are observable.

Posture, Not Target

The participants whose sessions scored highly went in with an intention they could let go of. They had a question they cared about, but they were not gripping it. The posture matters more than any specific intention content. Pre-session work that increases willingness to surrender, including breathwork, meditation, somatic practices, and integration of prior sessions, supports the score indirectly. Pre-session work focused on outcome-engineering suppresses it.

Dose Adequacy and Setting Matter

Sub-threshold doses produce sub-threshold MEQ-30 scores. The literature anchors on doses in the 20-to-30 milligram psilocybin range in most adult protocols, which produce reliable intensity in supportive settings. Settings that introduce ambient threat, including unfamiliar environments, unclear guide relationships, or unresolved logistical anxieties, compress the experience. Setting work is not aesthetic, it is signal-to-noise management.

Integration Capacity Is the Real Variable

The MEQ-30 score predicts outcome, but the integration arc is what converts the score into clinical change. A high score without integration support fades into a striking memory rather than a sustained shift. The participants whose six-month and twelve-month outcomes hold up are the ones who did the integration work, regardless of how strong their initial score was. The score predicts the ceiling. The integration determines whether you reach it. For deeper coverage, see the afterglow window and psychedelics for high-functioning depression.

The Decision-Making Implication

For founders weighing whether a psychedelic-assisted approach is worth pursuing, the MEQ-30 literature is part of the case for the upper bound of what is possible. It is not the case for any individual decision. Contraindication screening, clinician evaluation, and integration capacity all sit upstream of the score. The score becomes relevant once those upstream questions have been answered. For the related decision-making frame, see psychedelics and decision-making.

Frequently Asked Questions